Optimization of Allosteric Modulators of 5-HT2C Receptor
Optimization of Allosteric Modulators of 5-HT2C Receptor
批准号:
8243389
负责人:
Kathryn A. Cunningham
金额:
$22.95万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-02-17 至 2014-01-31
关键词:
Adverse eventAgonistAllosteric SiteAnxietyApplications GrantsBehaviorBindingBinding SitesBiologicalBiological AssayBiological ProcessBiological TestingCardiovascular systemCellsCentral Nervous System DiseasesCerebrospinal FluidChemical StructureChemicalsChinese Hamster Ovary CellClinical TreatmentCollaborationsDataDesire for foodDevelopmentDiseaseDrug DesignEating DisordersEndocrineEventExposure toFutureGoalsGrantHeadHumanInvestigationKnowledgeLeadLibrariesLifeLigand BindingLigandsMediatingMedicalMental DepressionMissionModificationMotorNervous system structureNeuraxisNeurobiologyNeuropharmacologyNociceptionObesityOutcomeParkinson DiseasePathologyPharmaceutical ChemistryPharmaceutical PreparationsPhase III Clinical TrialsPhysiologic ThermoregulationPhysiologicalPropertyPublic HealthReportingResearchResearch Project GrantsSchizophreniaScreening procedureSeriesSerotoninSerotonin Receptor 5-HT2CSignal TransductionSiteSpecificityStructure-Activity RelationshipTherapeuticTranslational ResearchValidationaddictionbasebehavioral pharmacologyburden of illnesschemical synthesisclinical applicationdesigndrug developmentfollow-upimprovedin vivoinnovationinsightnovelnovel strategiesnovel therapeuticspre-clinicalreceptorreceptor functionresearch studyresponsescaffoldsmall moleculesmall molecule libraries
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The modulation of 5-HT2C receptor (5-HT2CR) function holds a tremendous amount of therapeutic promise for the treatment of diseases of significant unmet medical need, including addiction, anxiety, depression, obesity/eating disorders and schizophrenia. Successful development of 5-HT2CR ligands requires selectivity versus the highly homologous 5-HT2AR and 5-HT2BR, because agonism at these receptors can result in serious CNS and cardiovascular adverse events. The rationale for this proposal is that allosteric modulators of the 5-HT2CR present a unique drug design strategy to augment the response to endogenous 5-HT in a site- and event-specific manner. This novel approach of using allosteric modulators of the 5-HT2CR to develop novel probes and therapeutics is very attractive since it is much easier to achieve high receptor subtype selectivity or even absolute specificity with a ligand binding to the allosteric site than with orthosteric ligands that bind to the endogenous ligand binding site. To date only one compound, PNU-69176E, has been identified via the compound library screening as a 5-HT2CR allosteric modulator. However, the relevant structure-activity relationship (SAR) studies were sparse, and thus our knowledge in this regard is quite limited. Our objective in this application is to optimize and develop allosteric modulators of the 5-HT2CR to generate novel, highly selective and potent 5-HT2CR ligands that will act as small molecule probes for the nervous system and novel therapeutics for CNS disorders. To accomplish this objective, we plan to pursue the following two specific aims: 1) Chemical synthesis and optimization of small molecules based on PNU-69176E as the chemical lead; and 2) Biological characterization of newly synthesized compounds using a cell-based signaling assay to identify allosteric modulators of 5-HT2CR with high potency, selectivity and better drug-like properties. This project is innovative, potentially high impact research that will aid in elucidating information about the chemical neurobiology of allosteric modulation of 5-HT2CR. Our results are expected to provide the valuable SAR and novel mechanistic insight into these chemically unique allosteric modulators of 5-HT2CR.The proposed studies will identify small molecules that will be utilized to probe the neurobiology of the 5-HT2CR. The long term goal of this project is to develop these modulators for preclinical validation and clinical application in translational research and ultimately as novel therapeutic candidates.
PUBLIC HEALTH RELEVANCE: This research project is highly relevant to public health because it entails chemical synthesis, optimization and pharmacological investigation of novel allosteric modulators of the 5-HT2C receptor that will act as small molecule probes for nervous system and novel therapeutics for a variety of CNS disorders of significant unmet medical need. Thus, the proposed research is relevant to the part of NIH's mission that pertains to developing new medications and fundamental knowledge that will help to lengthen life and to reduce the burdens of illness.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Addiction Neurocircuits in Cocaine Taking
-
批准号:10595681
-
项目类别:
-
资助金额:$48.88万
-
财政年份:2022
-
负责人:Kathryn A. Cunningham
-
依托单位:
Mechanisms of prenatal opioid exposure on brain and behavior
-
批准号:10375927
-
项目类别:
-
资助金额:$63.14万
-
财政年份:2022
-
负责人:Kathryn A. Cunningham
-
依托单位:
Novel Addiction Neurocircuits in Cocaine Taking
-
批准号:10375964
-
项目类别:
-
资助金额:$48.88万
-
财政年份:2022
-
负责人:Kathryn A. Cunningham
-
依托单位:
Mechanisms of prenatal opioid exposure on brain and behavior
-
批准号:10657323
-
项目类别:
-
资助金额:$63.14万
-
财政年份:2022
-
负责人:Kathryn A. Cunningham
-
依托单位:
NOP Receptor Antagonist for OUD Pharmacotherapy
-
批准号:10085851
-
项目类别:
-
资助金额:$279.38万
-
财政年份:2020
-
负责人:Kathryn A. Cunningham
-
依托单位:
Targeting the Ghrelin System for Novel Opioid Use Disorder Therapeutics
-
批准号:9905262
-
项目类别:
-
资助金额:$223.03万
-
财政年份:2019
-
负责人:Kathryn A. Cunningham
-
依托单位:
Targeting the Ghrelin System for Novel Opioid Use Disorder Therapeutics
-
批准号:10168769
-
项目类别:
-
资助金额:$23.74万
-
财政年份:2019
-
负责人:Kathryn A. Cunningham
-
依托单位:
Neural and Pharmacological Mechanisms of Abused Drugs
-
批准号:9404132
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Kathryn A. Cunningham
-
依托单位:
5-HT2 Receptor Allosterism in Cocaine Use Disorder
-
批准号:10445173
-
项目类别:
-
资助金额:$53.75万
-
财政年份:2015
-
负责人:Kathryn A. Cunningham
-
依托单位:
5‐HT2CR ALLOSTERIC MODULATORS AS NOVEL PHARMACOTHERAPY IN COCAINE USE DISORDER
-
批准号:9271312
-
项目类别:
-
资助金额:$0.89万
-
财政年份:2015
-
负责人:Kathryn A. Cunningham
-
依托单位:
5‐HT2CR ALLOSTERIC MODULATORS AS NOVEL PHARMACOTHERAPY IN COCAINE USE DISORDER
-
批准号:9480142
-
项目类别:
-
资助金额:$0.85万
-
财政年份:2015
-
负责人:Kathryn A. Cunningham
-
依托单位:
5-HT2 Receptor Allosterism in Cocaine Use Disorder
-
批准号:10621817
-
项目类别:
-
资助金额:$53.89万
-
财政年份:2015
-
负责人:Kathryn A. Cunningham
-
依托单位:
5‐HT2CR ALLOSTERIC MODULATORS AS NOVEL PHARMACOTHERAPY IN COCAINE USE DISORDER
-
批准号:9983267
-
项目类别:
-
资助金额:$10.71万
-
财政年份:2015
-
负责人:Kathryn A. Cunningham
-
依托单位:
Translational Addiction Sciences Center
-
批准号:8725105
-
项目类别:
-
资助金额:$129.76万
-
财政年份:2013
-
负责人:Kathryn A. Cunningham
-
依托单位:
Translational Addiction Sciences Center
-
批准号:8552186
-
项目类别:
-
资助金额:$129.3万
-
财政年份:2013
-
负责人:Kathryn A. Cunningham
-
依托单位:
Translational Addiction Sciences Center
-
批准号:8842966
-
项目类别:
-
资助金额:$128.05万
-
财政年份:2013
-
负责人:Kathryn A. Cunningham
-
依托单位:
Translational Addiction Sciences Center
-
批准号:9280892
-
项目类别:
-
资助金额:$138.76万
-
财政年份:2013
-
负责人:Kathryn A. Cunningham
-
依托单位:
Translational Addiction Sciences Center
-
批准号:9479888
-
项目类别:
-
资助金额:$1.69万
-
财政年份:2013
-
负责人:Kathryn A. Cunningham
-
依托单位:
Optimization of Allosteric Modulators of 5-HT2C Receptor
-
批准号:8429363
-
项目类别:
-
资助金额:$22.03万
-
财政年份:2012
-
负责人:Kathryn A. Cunningham
-
依托单位:
Inhibitors of 5-HT2CR Protein:Protein Interactions for Stimulant Pharmacotherapy
-
批准号:8311782
-
项目类别:
-
资助金额:$36.85万
-
财政年份:2010
-
负责人:Kathryn A. Cunningham
-
依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
-
批准号:32000851
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:乔安娜
-
依托单位: